CA2257890A1 - Liquisolid systems and methods of preparing same - Google Patents

Liquisolid systems and methods of preparing same

Info

Publication number
CA2257890A1
CA2257890A1 CA002257890A CA2257890A CA2257890A1 CA 2257890 A1 CA2257890 A1 CA 2257890A1 CA 002257890 A CA002257890 A CA 002257890A CA 2257890 A CA2257890 A CA 2257890A CA 2257890 A1 CA2257890 A1 CA 2257890A1
Authority
CA
Canada
Prior art keywords
coating materials
liquid
carrier
compressible
flowing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002257890A
Other languages
French (fr)
Other versions
CA2257890C (en
Inventor
Spiridon Spireas
Sanford M. Bolton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24641555&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2257890(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2257890A1 publication Critical patent/CA2257890A1/en
Application granted granted Critical
Publication of CA2257890C publication Critical patent/CA2257890C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Abstract

Liquisolid systems are acceptably flowing and compressible powdered forms of liquid medications. According to the concept of liquisolid systems, liquid liphophilic drugs or water-insoluble drugs dissolved in suitable non-volatile solvents may be converted into free-flowing and readily compressible powders by simple admixture with selected powder excipients referred to as carrier and coating materials; a schematic outline of steps may be drawn for the process.
Various grades of microcrystalline or amorphous cellulose may be used as carriers, whereas very fine particle size silica powders may be used as coating materials. Based on the theory that the carrier and coating materials can retain only certain amounts of liquid and at the same time maintain acceptable flow and compression properties, a new formulation-mathematical model is provided to calculate the optimum quantities of carrier and coating materials required to yield acceptably flowing and compressible liquid/powder admixtures.
CA002257890A 1996-06-10 1997-06-09 Liquisolid systems and methods of preparing same Expired - Lifetime CA2257890C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/658,514 1996-06-10
US08/658,514 US5800834A (en) 1996-06-10 1996-06-10 Liquisolid systems and methods of preparing same
PCT/US1997/010093 WO1997047290A1 (en) 1996-06-10 1997-06-09 Liquisolid systems and methods of preparing same

Publications (2)

Publication Number Publication Date
CA2257890A1 true CA2257890A1 (en) 1997-12-18
CA2257890C CA2257890C (en) 2003-10-28

Family

ID=24641555

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002257890A Expired - Lifetime CA2257890C (en) 1996-06-10 1997-06-09 Liquisolid systems and methods of preparing same

Country Status (13)

Country Link
US (2) US5800834A (en)
EP (1) EP0946154B1 (en)
JP (1) JP2000512295A (en)
CN (1) CN1224379C (en)
AT (1) ATE486584T1 (en)
BR (1) BR9709778A (en)
CA (1) CA2257890C (en)
DE (1) DE69740040D1 (en)
ES (1) ES2355871T3 (en)
HK (1) HK1022844A1 (en)
IL (1) IL127295A (en)
RU (1) RU2209623C2 (en)
WO (1) WO1997047290A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2159419C (en) * 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water
ATE462417T1 (en) 1998-08-13 2010-04-15 Cima Labs Inc MICROEMULSIONS AS SOLID DOSE FORMS FOR ORAL ADMINISTRATION
CA2355860C (en) * 1998-12-23 2010-03-30 Alza Corporation Dosage forms comprising porous particles
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6635281B2 (en) 1998-12-23 2003-10-21 Alza Corporation Gastric retaining oral liquid dosage form
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
US7029700B2 (en) * 2000-01-14 2006-04-18 Brown University Research Foundation Micronized freeze-dried particles
US7833549B2 (en) * 2000-01-19 2010-11-16 Mannkind Corporation Dry powder formulations of antihistamine for nasal administration
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
US7056951B2 (en) 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6855333B1 (en) 2000-10-03 2005-02-15 Mutual Pharmaceutical Co., Inc. Stabilization of solid thyroid drug formulations
US6979462B1 (en) 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
JP5684440B2 (en) * 2001-02-23 2015-03-11 シーマ・ラブス、インコーポレイテッド Compositions and solid formulations
US6692771B2 (en) 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
ITMI20012366A1 (en) * 2001-11-09 2003-05-09 Farmatron Ltd THERAPEUTIC SYSTEMS STABILIZED WITH IMMEDIATE RELEASE AND / OR MODIFIED FOR THE ORAL ADMINISTRATION OF ACTIVE AND / OR EXCIPIENT PRINCIPLES AND / OR WINGS
US6645526B2 (en) * 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) * 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
KR101170844B1 (en) * 2003-02-24 2012-08-02 파마슈티칼 프로덕션스, 인크. Transmucosal drug delivery system
EP1675571A2 (en) * 2003-09-30 2006-07-05 Spherics, Inc. Nanoparticulate therapeutic biologically active agents
CA2563739C (en) 2004-03-08 2013-07-09 Spiridon Spireas Bioavailable solid dosage forms of metaxalone
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
EP1791520A2 (en) * 2004-08-19 2007-06-06 Alza Corporation Controlled release nanoparticle active agent formulation dosage forms and methods
FR2894822B1 (en) * 2005-12-20 2011-11-18 Pf Medicament PHARMACEUTICAL COMPOSITION CONTAINING OMEGA-3 FATTY ACIDS
US7569612B1 (en) 2006-08-21 2009-08-04 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
WO2012027222A1 (en) 2010-08-24 2012-03-01 Rutgers, The State University Of New Jersey Formulation and manufacture of pharmaceuticals by impregnation onto porous carriers
CN102949363A (en) * 2012-11-28 2013-03-06 山东省中医药研究院 Ursolic acid liquid-solid compression tablet
US10660856B2 (en) 2013-02-01 2020-05-26 W. R. Grace & Co.-Conn. Porous silica gel as a carrier for liquid technologies
GB201812022D0 (en) * 2018-07-24 2018-09-05 Univ Of Sussex Pharmaceutical methods and compositions
US10744137B1 (en) * 2020-01-06 2020-08-18 King Abdulaziz University Liquisolid tablet containing combined dose of tadalafil and dapoxetine
CN111067875B (en) * 2020-01-16 2021-11-30 兰州大学 Albendazole liquid-solid compressed tablet and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1368112A (en) * 1971-09-08 1974-09-25 Geistlich Soehne Ag Chemical compositions for the treatment of hyperlipemia
DE2400819C2 (en) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Process for the production of solid preparations of poorly soluble active pharmaceutical ingredients in extremely fine distribution

Also Published As

Publication number Publication date
US5968550A (en) 1999-10-19
EP0946154A4 (en) 2007-02-07
ES2355871T3 (en) 2011-03-31
EP0946154B1 (en) 2010-11-03
EP0946154A1 (en) 1999-10-06
WO1997047290A1 (en) 1997-12-18
CN1221337A (en) 1999-06-30
IL127295A (en) 2002-05-23
US5800834A (en) 1998-09-01
JP2000512295A (en) 2000-09-19
CN1224379C (en) 2005-10-26
RU2209623C2 (en) 2003-08-10
HK1022844A1 (en) 2000-08-25
DE69740040D1 (en) 2010-12-16
AU3387097A (en) 1998-01-07
BR9709778A (en) 2000-01-11
IL127295A0 (en) 1999-09-22
ATE486584T1 (en) 2010-11-15
CA2257890C (en) 2003-10-28
AU709566B2 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
CA2257890A1 (en) Liquisolid systems and methods of preparing same
TW343977B (en) Production of modified polytetrafluoroethylene granular powder
CA2166891A1 (en) Method for making freeze dried drug dosage forms
AU6823200A (en) Powders consisting of particles with a perfectly smooth surface, for use as carriers for the preparation of inhalation mixtures with micronized drugs and methodfor their preparation
CA2132344A1 (en) Super porous polysaccharide gels
MXPA03001181A (en) Expanded perlite products with controlled particle size distribution.
CA2115065A1 (en) Ultrafine Particle Powder for Inhalation and Method for Production Thereof
IL111080A0 (en) Process for producing powders
TW375655B (en) Process for preparing a granular detergent
ZA929161B (en) Microcrystalline cellulose spheronization composition.
AU3031597A (en) Dispersion process
CA2430318A1 (en) Powder formulation and method for producing the same
CA2083651A1 (en) Redispersible powder composed of n-vinylpyrrolidone/vinyl acetate copolymer, the preparation and use thereof
TW360542B (en) Method of producing porous delivery devices
WO1998051748A1 (en) Granulated powdery paint and process for producing the same
AU581530B2 (en) Process for the preparation of granules and granules obtained by this process
EP0395095A3 (en) Metastable metal colloids and preparation
EP0669135A4 (en) Granular preparation for mri.
GB1462633A (en) Granulating urea
Masterson et al. Cultural Differences in Public Speaking.
KR960705562A (en) Granular preparation
GR3020086T3 (en) Powder precursor product.
WITT Preparation of InP by solution and melt growth techniques[Final Technical Report, 1 Nov. 1978- 30 Nov. 1980]
JPS53124565A (en) Preparation of powdered resin
Jozsef The situation and problems of the Hungarian steel industry

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170609